Clinical Development & Data
Trial architecture, endpoints, recruitment, comparator signals, investigator interpretation, and the way evidence in neuroscience will be read downstream.
Neuroscience
ICG works across neuroscience environments where endpoints, physician interpretation, diagnostic pathways, patient segmentation, delivery, reimbursement, and field organization interact.
The work includes neuroscience competitive intelligence, sleep and migraine research, neurodegeneration, psychiatry, multiple sclerosis, neurotoxins, clinical and regulatory assessment, launch strategy, and longitudinal monitoring.
Signals Become Decisions Through Interpretation.
Neuroscience markets are shaped by uncertain endpoints, heterogeneous populations, evolving biomarkers, specialist and primary-care boundaries, administration burden, and the credibility of functional outcomes.
ICG reconstructs how evidence is interpreted by investigators, clinicians, regulators, payers, companies, and patients—and how that interpretation changes development, launch, and portfolio choices.
Decision Environments
Engagements begin at different points, but the governing constraints often cross the boundaries of the initial request.
Regulatory & Access Pathways
Filing logic, label conditions, evidence requirements, reimbursement, pathway position, and country-level adoption constraints.
Launch & Commercial Architecture
Market preparation, field-force and medical roles, account coverage, channel structure, patient support, and launch sequencing.
Manufacturing & Delivery
Capacity, supply, configuration, administration, device or site readiness, and the relationship between operational uncertainty and asset value.
Patient & Treatment Systems
Patient identification, referral patterns, specialist pathways, administration burden, monitoring, persistence, and continuity of treatment.
Longitudinal Competitive Monitoring
Clinical, regulatory, access, organization, and commercial signals reconstructed across multi-phase and multi-year programs.
Evidence Architecture
The evidence base is developed through source calls and interviews positioned close to the decisions, constraints, and operating conditions being reconstructed.
Clinical & Investigator Side
Key opinion leaders, principal investigators, study-site personnel, treating specialists, centers of excellence, diagnostic pathways, and investigator-side clinical teams.
Company-Side Sources
Clinical development, regulatory, medical affairs, CMC and manufacturing, market access, patient services, field leadership, commercial, and portfolio functions.
Access & Operating Systems
Payer and reimbursement environments, procurement, distribution, treatment centers, testing providers, administration systems, patient-support infrastructure, and local access pathways.
Triangulation
Interview evidence is tested against clinical, regulatory, manufacturing, access, and organizational signals and against the criteria used by reviewers, payers, clinicians, partners, and other decision-makers.
Selected Project Record
Selected engagements across neuroscience.
The projects below are selected from a substantially larger body of work. They were chosen to illustrate different decision environments, lifecycle stages, modalities, geographies, and forms of engagement. The selection is illustrative rather than exhaustive. Multi-phase and longitudinal assignments may be presented as a single project title, and company, asset, or market details may be generalized where appropriate.
Clinical Development & Data
- Clinical-Development and Commercial Assessment of Orexin Agonists in Narcolepsy and Idiopathic Hypersomnia
- Real-World Evidence Generation and Clinical-Trial Design for an Alzheimer's Disease Therapy
- Clinical and Commercial Strategy for a Major Depressive Disorder Therapy in the United States and Canada
- Clinical-Development Assessment of Therapies in Fragile X Syndrome
- Endpoint and Trial-Design Assessment for Rett-Syndrome Gene Therapies
Regulatory, Access & Adoption
- Market-Access and Adoption Assessment for Alzheimer's Disease Biomarkers and Therapies
- Reimbursement and Prescriber Architecture for Migraine Therapies in Emerging Markets
- Access and Treatment-Pathway Assessment for Neuromyelitis Optica Spectrum Disorder
- Regulatory and Adoption Architecture for Novel Neurotoxins in Adult Spasticity
- Patient-Identification and Referral Pathways in Narcolepsy and Idiopathic Hypersomnia
Launch & Commercial Architecture
- Longitudinal Competitive and Launch Monitoring in Migraine Across Europe and Selected International Markets
- Franchise Strategy for Neuromyelitis Optica Spectrum Disorder
- Multiple-Sclerosis Talent, Field-Force and Mobile-Engagement Architecture
- Launch and Commercial Assessment of Orexin-Based Therapies in Sleep Disorders
- Commercial Architecture for ADHD Therapies Following Generic Entry in the United States
Manufacturing, Delivery & Systems
- Device and Specialty-Pharmacy Strategy for Multiple-Sclerosis Therapies
- Manufacturing-Capability Assessment for Botulinum-Toxin Portfolios
- Digital-Engagement and Patient-Support Architecture in Multiple Sclerosis
- Delivery-System Assessment for Long-Acting Therapies in Schizophrenia
- Diagnostic and Biomarker Workflow Assessment in Alzheimer's Disease
Longitudinal Monitoring & Portfolio
- Multi-Market Generic-Entry, Device and Specialty-Pharmacy Strategy for Multiple Sclerosis
- Longitudinal Monitoring of Orexin Programs Across Narcolepsy and Insomnia
- Competitive Monitoring Across Migraine Portfolios in Europe and Selected Markets
- Portfolio Monitoring Across Neurodegeneration, Psychiatry and Sleep Medicine
Neuroscience Engagements
ICG can enter at the level of a single critical question, a multi-market evidence program, or a longitudinal clinical, regulatory, manufacturing, access, commercial, or operating-system decision environment.